Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice
Angelo O. Rosa(Universidad Autónoma de Madrid), Ana Lúcia S. Rodrigues(Universidade Federal de Santa Catarina), Miguel Medina(Baptist Hospital of Miami), Marı́a Luisa Navarro-Rico(Instituto de Salud Carlos III), Manuela G. López(Hospital Universitario de La Princesa), Ricardo W. Binfaré(Universidade Federal de Santa Catarina), Ester Martı́n-Aparicio(Universitas Gadjah Mada), Susana Morales(Universitas Gadjah Mada), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Antonio G. Garcı́a(Universidad Complutense de Madrid), Manuella P. Kaster
Progress in Neuro-Psychopharmacology and Biological Psychiatry
May 31, 2008
Cited by 128
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings
|Brain Behavior and Immunity|2017|375
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334